YOLFTbeta
EQL Pharma AB

EQL Pharma AB

EQL · ST · Healthcare / Drug Manufacturers - Specialty & Generic

25.00SEK+0.15 (+0.60%)

Price History

Full chart

Market Stats

Previous Close24.85
Open25.25
Day Range24.85 – 25.50
52-Week Range17.38 – 67.50
Volume3.32K
Market Cap690.99M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.51
Dividend Yield0.00%
Beta0.26
50-Day Avg24.16
200-Day Avg39.45

About

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Axel Schorling
  • Employees65
  • HeadquartersStortorget 1, Lund, Sweden, 222 23, Sweden
  • Websitehttps://www.eqlpharma.com

Leadership

  • Mr. Christer Fahraeus B.Sc. Maths, h.c., MSc Bio Eng, Ph.D.Founder & Chairman · b. 1965
  • Mr. Axel SchorlingPresident & CEO · b. 1986
  • Mr. Allan Sylvest AasbergChief Financial Officer · b. 1975
  • Martin KristoffersonChief Operating Officer · b. 1978
  • Ms. Anna JonssonHead of Accounting · b. 1984
  • Ms. Anne Drew JensenChief Sales Officer · b. 1992
  • Mr. Magnus ErrethCQSCO & Supply Chain Officer · b. 1977
  • Ms. Ivana AntolasChief of Quality · b. 1985

Financials

Income Statement

Currency: SEK2021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue179.14M409.75M259.91M264.17M373.52M432.66M
Growth (%)-+128.73%-36.57%+1.64%+41.39%+15.83%
Cost of Revenue128.13M314.02M144.06M149.12M217.56M269.82M
Gross Profit51.01M95.73M115.85M115.05M155.95M162.84M
Gross Margin28.47%23.36%44.57%43.55%41.75%37.64%
Operating Expense39.81M57.17M74.74M82.80M89.60M115.46M
Operating Income11.19M38.56M41.11M32.24M66.35M47.38M
Operating Margin6.25%9.41%15.82%12.21%17.76%10.95%
EBITDA--41.34M43.08M79.21M67.69M
EBITDA Margin--15.91%16.31%21.21%15.64%
Net Income10.37M31.55M30.92M22.70M43.12M12.54M
Net Income Margin5.79%7.70%11.90%8.59%11.55%2.90%
R&D11.70M9.13M15.14M12.09M11.26M14.33M
R&D as % of Total Revenue6.53%2.23%5.82%4.58%3.02%3.31%
Interest Expense1.10M2.87M2.37M5.73M12.34M26.39M
Interest Expense % of Total Revenue0.61%0.70%0.91%2.17%3.30%6.10%

Balance Sheet

Currency: SEK2021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets203.51M237.89M285.70M373.76M808.82M850.89M
Total Liabilities112.29M114.26M130.94M196.03M587.79M583.83M
Total Equity91.22M123.63M154.75M177.73M221.03M267.06M
Cash26.58M41.20M44.43M20.47M82.40M86.76M
Net Debt55.83M30.72M19.27M97.20M369.16M398.39M

Cash Flow

Currency: SEK2021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow60.05M41.83M27.62M-11.44M-24.65M28.36M
Capital Expenditure55.58M22.09M20.51M66.26M245.84M67.24M
Free Cash Flow4.47M19.74M7.11M-77.70M-270.49M-38.88M
FCF to OCF7.44%47.19%25.74%679.37%1097.25%-137.09%

Earnings

Report DateMar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Dec 31, 2016Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Jun 30, 2022Feb 13, 2024May 14, 2024Aug 8, 2024Nov 6, 2024Feb 5, 2025May 8, 2025Aug 8, 2025Nov 5, 2025Feb 3, 2026May 8, 2026Aug 7, 2026
EPS Estimate-----------------------0.320.190.280.220.330.480.41-0.060.280.11-0.04
EPS Actual-0.20-0.16-0.10-0.12-0.01-0.010.020.01-0.05-0.06-0.040.000.040.050.010.390.110.07-0.210.090.180.590.250.220.160.420.330.350.440.33-0.110.33-0.13-0.03
Surprise------------------------31.25%-15.79%50.00%50.00%6.06%-8.33%-19.51%-83.33%17.86%-218.18%25.00%
Timing-----------------------After-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap690.99M
Enterprise Value1.11B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.60
Price / Book2.75
EPS-0.51
Book Value8.48
Revenue (TTM)432.35M
Gross Profit (TTM)134.53M
EBITDA34.31M
Profit Margin-3.25%
Operating Margin-12.74%
Return on Equity-5.84%
Return on Assets1.06%
Shares Outstanding29.53M
Shares Float12.80M
Beta0.26
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%